

Supplemental data

Supplementary Table 1:

Patients' characteristics	N (%)
Age	
Gender:	
Men	30 (83.3)
women	6 (16.7)
BMI (mean)	29.5
Hypertension	16 (44.4)
Diabetes mellitus	17 (47.3)
Obesity	18 (50.0)
Cardiovascular disease	3 (8.3)
Chronic lung disease	3 (8.3)
Cancer[^]	2 (5.5)
Chronic kidney disease	2 (5.5)
Smoking	3 (8.3)

Supplementary Table 1: Patient characteristics. [^], Hematological malignancy (Chronic lymphocytic leukemia, AML in remission after Bone marrow transplant).

Supplementary Table 2:

	Patients with AKI	Patients without AKI
Number (%)	(22 (61.1))	14 (38.9)
Age- mean (median)	63.7 (67)	57.1 (60)
Diabetes	12 (54.5)	5 (35.7)
Hypertension	13 (59.1)	3 (21.4)
Chronic renal failure (%)	2 (9.1)	0
AKI upon admission (%)	8 (36.4)	0
Renal replacement therapy (%)	13 (59.1)	0
ECMO (%)	5 (22.7)	4 (28.6)
Mortality	14 (63.3)	4 (28.6)
Days to develop AKI- mean (median)	6.4 (4)	-
Days to maximal creatinine- mean (median)	15.3 (12.5)	-
Documented hypotension prior to AKI	19 (77.3)	
Sepsis (bacterial/fungal) prior to AKI	9 (36.4)	
Cardiovascular collapse prior to AKI	6 (27.3)	
AKI on the day of intubation	6 (22.7)	
Rhabdomyolysis prior to AKI	0	
Urinary retention > 500 ml (before catheterization)	0	
Creatinine (mg/dL), mean (median)		
At admission	1.2 (0.97)	0.75 (0.78)
Peak level	3.51 (3.42)	0.85 (0.9)
Final documented value	1.74 (1.34)	0.55 (0.56)
Urea (mg/dL), mean (median)		
At admission	51.72 (43.5)	32.5 (34)
Peak level (at maximal creatinine)	167.13 (164.5)	50.14 (44.5)
Final documented value	98.68 (91.5)	53.64 (36)
Urea to creatinine ratio		
At admission	43.10	43.33
Peak level (at maximal creatinine)	47.62	58.99
Final documented value	56.71	97.53

Supplementary Table 2: Comparison of clinical characteristics of COVID-19 patients with and without AKI.

